^
Association details:
| Biomarker: | FGFR3 mutation |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | CTLA4 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma
Published date:
11/08/2022
Excerpt:
Patients in the ICIs-treated cohort were all subjected to ICIs treatment, including anti-PD-(L)1 or anti-CTLA-4….In the ICIs-treated cohort, patients with FGFR mutations had better survival than those without (median overall survival: 60.00 vs. 31.00 months; hazard ratio: 0.58, 95% CI: 0.42-0.80; P = 0.0051). Besides, the objective response rate was higher for patients harboring FGFR mutations (55.56%) compared to wild-type patients (22.40%) (P = 0.0076)....Our study demonstrated that FGFR mutations is a promising biomarker in stratifying patients with advanced melanoma who might benefit from ICIs therapy.
DOI:
10.3389/fimmu.2022.1030969
